Abstract 27
Background Incidence of neonatal sepsis increases with decreasing gestational age and is most frequently associated with neutropenia in babies <1500g. Haemopoietic growth factors may be of benefit, but safety in sick, neutropenic, septic neonates has not previously been evaluated.
Aims To assess safety of rhG-CSF in septic preterm babies, with relative or absolute neutropenia. Secondary objectives were to evaluate mortality and preliminary markers of efficacy.
Methods 28 Neonates requiring intensive care, of >25 weeks gestation, with birth weights 500-1500g were recruited if the ANC (absolute neutrophil count) was <5×109/l, when they received antibiotics for documented or suspected sepsis. Randomised babies received either placebo or 10 mcg/kg/day rhG-CSF iv, for a maximum of 14 days. ANC and a number of potential treatment-related adverse events were evaluated, including thrombocytopenia.
Results Infection was confirmed in 8/15 control and 6/13 rhG-CSF-treated babies, and probable in 6/15 and 5/13 respectively. Median (range) days to ANC recovery was 2 (1-5) in the rhG-CSF group compared to 5 (1-30) in controls (p<0.001). One death occurred in the rhG-CSF group compared to 4 in controls (NS). Thrombocytopenia occurred in 7/15 controls and 2/13 of the treatment group (p<0.05). Overall treatment-related adverse side-effects occurred in 6/15 controls versus 2/13 of rhG-CSF-treated babies (NS).
Conclusions Used as an intervention during confirmed or probable sepsis, rhG-CSF increased ANC recovery with no acute adverse events, but efficacy remains unproven.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bedford Russell, A., Emmerson, A., Wilkinson, N. et al. UK multicentre prospective, randomised, double-blind, placebo-controlled trial of rhG-CSF (granulocyte colony-stimulating factor) in neonatal sepsis. Pediatr Res 45, 891 (1999). https://doi.org/10.1203/00006450-199906000-00045
Issue Date:
DOI: https://doi.org/10.1203/00006450-199906000-00045